Key Insights into BioNTech SE Stock

By Kim Brooks • Monday, January 13 10:12 • Permanent Link

BioNTech SE logged a -3.8% change during today's morning session, and is now trading at a price of $118.14 per share. The S&P 500 index moved -1.0%. BNTX's trading volume is 293,152 compared to the stock's average volume of 826,029.

BioNTech SE trades -13.2% away from its average analyst target price of $136.12 per share. The 20 analysts following the stock have set target prices ranging from $117.64111 to $170.54301, and on average have given BioNTech SE a rating of buy.

If you are considering an investment in BNTX, you'll want to know the following:

BioNTech SE's current price is 38.8% above its Graham number of $85.09, which implies that at its current valuation it does not offer a margin of safety
BioNTech SE has moved 23.4% over the last year, and the S&P 500 logged a change of 22.3%
Based on its trailing earnings per share of -2.0, BioNTech SE has a trailing 12 month Price to Earnings (P/E) ratio of -59.1 while the S&P 500 average is 29.3
BNTX has a forward P/E ratio of -30.3 based on its forward 12 month price to earnings (EPS) of $-3.9 per share
Its Price to Book (P/B) ratio is 1.48 compared to its sector average of 3.53
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.
Based in Mainz, the company has 6,133 full time employees and a market cap of $28.32 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.